BUSATO, DAVIDE
A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma
2023-01-01 Busato, Davide; Capolla, Sara; Durigutto, Paolo; Mossenta, Monica; Bozzer, Sara; Sblattero, Daniele; Macor, Paolo; Dal Bo, Michele; Toffoli, Giuseppe
A novel epigenetic machine learning model to define risk of progression for hepatocellular carcinoma patients
2021-01-01 Bedon, L.; Dal Bo, M.; Mossenta, M.; Busato, D.; Toffoli, G.; Polano, M.
Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies
2020-01-01 Mossenta, Monica; Busato, Davide; Dal Bo, Michele; Toffoli, Giuseppe
Glypican 1-targeted therapeutic approaches adopting doxorubicin-loaded chitosan nanobubbles and antibody-based strategy in the context of Pancreatic Ductal Adenocarcinoma
2022-09-19 Busato, Davide
Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma
2025-01-01 Mossenta, M; Argenziano, M; Capolla, S; Busato, Davide; Durigutto, P; Mangogna, A; Polano, M; Sblattero, D; Cavalli, R; Macor, P; Toffoli, G; Michele Dal Bo,
New insight into therapies targeting angiogenesis in hepatocellular carcinoma
2019-01-01 Mossenta, Monica; Busato, Davide; Baboci, Lorena; DI CINTIO, Federica; Toffoli, Giuseppe; Dal Bo, Michele
The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells.
2024-01-01 DI CINTIO, Federica; Argenziano, M; Scomparin, A; Capolla, S; Busato, D; Steffè, A; Mangogna, A; Sblattero, D; Cavalli, R; Macor, P; Michele Dal Bo, ; Toffoli, G